This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	CD27; CD70 (CD27L)	<p>Cell culture and mouse studies suggest blocking CD27-CD70 interactions could help treat CML. In a mouse model of CML, deletion of Cd27 or an anti-CD70 antibody decreased wingless-type MMTV integration site (WNT) signaling and prolonged survival compared with normal Cd27 expression or an IgG control, respectively. Next steps could include clinical development of anti-CD27 or anti-CD70 antibodies to treat CML.</p> <p>CDX-1127, a human mAb against CD27 from Celldex Therapeutics Inc., is in Phase I testing to treat cancer.</p> <p>Seattle Genetics Inc.'s SGN-75, an antibody-drug conjugate composed of an anti-CD70 mAb and monomethyl auristatin F₁, is in Phase I trials to treat cancer.</p> <p>MDX-1203, a cytotoxic prodrug chemically linked with a human anti-CD70 antibody from Bristol-Myers Squibb Co., is in Phase I testing to treat cancer.</p> <p>SciBX 5(4); doi:10.1038/scibx.2012.94 Published online Jan. 26, 2012</p>	Patent and licensing status unavailable	<p>Schürch, C. <i>et al. J. Clin. Invest.</i>; published online Jan. 9, 2012; doi:10.1172/JCI45977</p> <p>Contact: Adrian F. Ochsenbein, University Hospital Bern, Bern, Switzerland e-mail: adrian.ochsenbein@insel.ch</p>